News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

G Medical Innovations (NASDAQ: GMVD) is forecasting incremental Q1 revenues at around $30 MM, based on revenue generated from G Medical Tests and Services’ physical storefront testing locations

G Medical Innovations Holdings

Dr. Yacov Geva, President and CEO of G Medical Innovations, and Michael McDade, CEO of McDade Products, LLC, announced today that they acquired an undisclosed number of shares of G Medical Innovations (NASDAQ: GMVD). The CEO of McDade Products, LLC cited high confidence levels for sales of the co-branded LiveNow COVID-19 PCR Test Collection Kits announced this week and the forecasting of $30MM in revenues generated from the successful storefront COVID-19 testing locations operated by the company’s G Medical Tests and Services division. G Medical Tests and Services currently operates storefront testing locations in California. During the next few months, the company expects to expand its network of storefront testing locations in California and other U.S. regions to be announced at a later date. Pittsburgh-based McDade Products, LLC and G Medical Tests and Services have partnered to make millions of FDA EUA-approved COVID-19 PCR collection test kits available for retailers to sell by the end of January, in response to a national shortage of COVID-19 test options. The LiveNow COVID-19 PCR Test Collection Kits provide 24–48-hour certified lab results and retail for $9.99. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. “With the U.S. government’s shift to emphasize COVID-19 testing to combat this virus, I’ve acquired stock with G Medical on the open market because I strongly believe in the future of the company. As a trusted and proven mobile health and e-health company, G Medical is now making SARS-CoV2 certified lab testing even more accessible and convenient for consumers,” said Michael McDade, CEO of McDade Products, LLC. McDade Products is a division of McDade Group, a privately held specialty sales, marketing, and distribution company serving the U.S. retail industry. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 14, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

McDade Products, LLC and G Medical Tests Secure Additional Purchase Order for $6.5 Million, Reflecting $3.5 Million Gross Margin, to be Delivered in Q1

G Medical Innovations Holdings

PITTSBURGH, PA – McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), today announced an additional $6.5 million purchase order for two million COVID-19 PCR collection test kits. G Medical will be selling these units wholesale for $3.25 each, reflecting a gross profit of approximately $3.5 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. “McDade is pleased to be expanding upon its existing purchase order so quickly and expects to be ordering a further seven million test kits in the next thirty days.” These orders seem to come at a pertinent moment with the Biden Administration recently requiring that private insurers pay for a minimum of eight COVID 19 test kits per person per month starting January 15 th. G Medical Tests and Services is delighted to provide McDade with current and future purchase orders. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders and anticipated gross profits. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 12, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

Most Lives Saved by Organ Transplant in a Single Year

United Network for Organ Sharing

In 2021, a historic 41,354 organ transplants were performed in the U.S., an increase of 5.9 percent over 2020 and the first time the annual total exceeded 40,000, according to preliminary data from United Network for Organ Sharing (UNOS), the engine that powers the nation’s organ donation and transplantation system. The three organs most commonly transplanted also set annual records. There were 24,669 kidney transplants, 9,236 liver transplants and 3,817 heart transplants in 2021. Liver transplant totals have set annual records for the past nine years, and heart transplants have set a new record every year for the past decade. “We are gratified that transplantation continues to increase substantially and meet the needs of many more people with organ failure, despite ongoing challenges to healthcare relating to the COVID-19 pandemic,” said Matthew Cooper, M.D., FACS, president of the UNOS Board of Directors. “This speaks to the dedication and collaboration of donor hospitals, organ procurement organizations and transplant hospitals striving to ensure every opportunity to give the gift of life is pursued and celebrated." Thanks to the generosity of selfless donors and their courageous families, deceased organ donations continued its 11-year record trend. Increases in donation occurred in many areas throughout the nation. Of 57 organ procurement organizations (OPOs), 49 experienced an increase in donation over their 2020 total. Forty-five OPOs set all-time records for donors recovered in a single year. “As always, we are indebted to the many thousands of people who make these transplants possible through the selfless gift of organ donation,” Cooper said. “And we are reminded daily of our need to help the tens of thousands of men, women and children continuing to await a lifesaving transplant.” Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Dr. Cooper is a transplant surgeon and the director of kidney and pancreas transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN ) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 11, 2022 11:20 AM Eastern Standard Time

Image
Article thumbnail News Release

GLOBAL INDUSTRY LEADER NEAL GUTTERSON JOINS GROUNDWORK BIOAG’S ADVISORY BOARD

Groundwork BioAg

Groundwork BioAg® expanded its advisory board with the addition of Neal Gutterson, PhD, Chief Technology Officer and Partner at Radicle Growth and recently retired Chief Technology Officer at Corteva. Recognized as a world-class scientist in agricultural biotechnology, Gutterson brings in-depth experience advancing innovation and biological platforms to deliver greater value to farmers around the world. “Innovation in biologicals and regenerative practices are helping to restore soil health and carbon permanence while ensuring plant nutrition, with less phosphorus fertilizer. But more must be done to accelerate mainstream adoption of these solutions and engage everyone across the food supply chain—from farmers to consumers—to restore overall sustainability. At Groundwork BioAg, this is our mission. We look forward to working with Neal as our advisor and are delighted to tap into his unique experiences,” said Dr. Yossi Kofman, Co-Founder and Chief Executive Officer at Groundwork BioAg. Prior to his role at Corteva, Gutterson led Mendel Biotechnology as CEO, where he expanded the company’s plant gene network platform to improve productivity, resource use efficiency and stress tolerance of key agricultural crops. Today, Gutterson serves as CTO and Partner at Radicle Growth and on the System Board of CGIAR. In the past, he has served on the Board of Directors for the International Maize and Wheat Improvement Center (CIMMYT) as well as several organizations focused on technology advancements that improve the overall sustainability of crop production. “Tremendous progress has been made to expand biological innovation in the last decade, however, to combat climate change and restore the overall health of our food supply, we must look deeper into our soils,” said Gutterson. “I’m delighted to join Groundwork BioAg’s advisory board to help the company achieve the full potential of its proven science, while tackling existential challenges like permanent soil carbon sequestration and chronic drought.” In 2021, Groundwork BioAg accelerated mass production of its highly concentrated, cost-effective mycorrhizal inoculants and unlocked its technology platform to quickly scale product development. The company has consistently delivered year-over-year sales growth and expanded its global presence. In addition to increasing yield, Groundwork BioAg’s mycorrhizal inoculants improve sustainability by reducing dependency on phosphorus fertilizer and improving carbon sequestration in soil. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 11, 2022 08:00 AM Central Standard Time

Image
Article thumbnail News Release

Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX

Appyea

World renowned machine learning and bio-feedback expert joins company to execute and lead the development of DreamIT – the company’s patented solution integrating its proprietary AI technology in a wearable data driven wristband to treat sleep apnea and snoring. SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced today the appointment of Biomedical AI entrepreneur Prof. Amir Geva, as its chief science officer. Prof. Geva is a world-renowned expert in the field of machine learning, with over 25 years of business leadership experience as the founder and R&D teams leader of biomedical AI companies Elminda, InnerEye and WideMed. He brings over 40 years of deep AI research, serving today as the Head of the Biomedical Signal Processing and Machine Learning Lab and as Professor at the Electrical and Computers Engineering Department at Ben Gurion University of the Negev in Israel. As of today, Prof. Geva had published 62 scientific articles, and he is Senior Member at the Biomedical Engineering and Computers of the IEEE. In the past he had served also as consultant to the Israeli Air Force and Elbit on bioelectrical signal processing. He is DSc in Biomedical Engineering from the Technion Israel Institute of Technology, and formerly a Major at the Israeli Navy. "SleepX’ is the right solution many had been waiting for", Prof. Amir Geva commented. "The company has introduced a revolutionary combination of sensor technology, data analysis and machine learning to take on the challenge sleep-training for adults and improving people’s sleep and general wellbeing. I look forward to working with the team to complete the development of the company’s product and realize its market potential." SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. "We are honored to have a world expert in bio-feedback and AI such as Prof. Geva joining us to lead the development of our product’s brain analysis capabilities and advance the execution of our go-to-market strategy to realize the company’s business plan", said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

January 11, 2022 08:24 AM Eastern Standard Time

Image
Article thumbnail News Release

Elsevier launches Complete Anatomy female model, the most advanced full female anatomy model available in the world

Elsevier

The innovative 3D solution marks a major milestone in education equality with the representation of the full female anatomy in the study of the human body The launch is coming at a time when females are more likely to be misdiagnosed for health conditions compared to male counterparts Elsevier, a global leader in research publishing and information analytics, is pleased to announce the launch of the most advanced 3D full female model ever available, as part of the latest addition to its 3D platform, Complete Anatomy. This marks the first time that a female model has been built with this level of detail in its entirety, to represent the female — versus replacing specific areas of the male anatomy with female features. The solution allows educators to visualize, edit and teach anatomy entirely from the female perspective for the first time, all in stunningly realistic 3D detail. Complete Anatomy is a revolutionary cloud-based medical education platform from 3D4 Medical by Elsevier and is the No. 1 top-selling medical category app on iPad in the U.S., with over 20 million downloads globally. The launch signifies a major milestone in equal representation by preparing medical, nursing and allied health students with the most complete understanding of the female anatomy. Historically, the full female anatomy has been underrepresented in the study of the human body. Now, educators can choose the sex with which they’d like to teach their full curriculum, in addition to having the option of switching between male and female anatomies to teach comparative differences in sex-specific regions of the body. The Complete Anatomy female model provides educators with a more comprehensive teaching approach that allows them to switch seamlessly between teaching both female and male anatomy. Elizabeth Munn, Managing Director, Global Medical Education, Elsevier, said: “As an advocate for content that is diverse and inclusive, we are thrilled to offer this groundbreaking full female model to allow educators to teach anatomy in an equal and comprehensive way. Complete Anatomy is continuing Elsevier’s rich heritage of innovation in education by delivering on our vision of providing transformative medical education solutions. We are proud to take this step forward in addressing gender bias and believe Complete Anatomy’s female model will have a tremendous impact on the educational experience of medical students worldwide as well as on the outcomes of patients they treat in the future.” Informed by four years of expert research and development, anthropological data from specialist texts, academic papers and customer feedback, the addition of the female model to Complete Anatomy’s 3D platform provides an unprecedented opportunity to study the female form in more detail than before. Complete Anatomy’s female model will benefit all courses that teach anatomy and is an essential virtual tool for learners studying outside the lab who need a deeper understanding of both male and female anatomies. The Complete Anatomy female model includes: The full skeletal system — A complete female skeletal system includes a wide array of unique features, rarely seen in anatomical texts. Sexual differences have been applied to areas such as the pelvis and skull. Long bones have been proportioned, and bone angles accurately reflect the uniquely female architectural skeletal base. Accurate portrayal of muscles — To create an accurate representation of the female anatomy, the overall volume of muscle mass for each muscle has been reduced by roughly 30%, in line with research findings from the broadest demographic of females as compared to males. Visually detailed female-specific regions — The female-specific regions have been created in detail that is equivalent to the male counterpart. Breast tissue can be hemisected or quartered to reveal the underlying tissues with a more accurate distribution and representative state of the mammary glands, now shown as nonlactating, unlike most anatomical resources. The reproductive organs from the internal and external genitalia have been remodeled to accurately show their continued relationship. Comparative functionality — Users can switch between models for comparative study on any part of the male and female forms, compare sexual differences and reveal the origin and distribution of nerves. Users can learn continuity from a “Gray’s Anatomy”-inspired atlas and dissection course, take quizzes and watch videos to test their skills. Lead subject matter expert on the update Yasmin Carter, PhD, Assistant Professor of Translational Anatomy at the UMass Chan Medical School, Worcester, MA, USA said: “One of the inherent dangers in using only the male body as ‘anatomical normal’ and the female body as a variation, is perpetuating sexist attitudes. This unconscious bias will be carried by learners into their future interactions with the body, including potentially with patients. Complete Anatomy is creating a platform of representation that is diverse, balanced, and most importantly, accurate. By giving educators the option to choose the female body as the basis for their students’ education, Elsevier is helping evolve equitable teaching practices by normalizing the female body. Complete Anatomy’s female model will support me in training the next generation of medical professionals to be more appropriate and inclusive.” Elsevier has been working continuously to enhance its global portfolio of medical education solutions, digital learning tools and analytics for medical and nursing students to prepare them for successful careers in health professions. Recently, Elsevier announced the acquisition of Osmosis, a visual learning platform for medical students and professionals, which followed other acquisitions in nursing and health education, including Shadow Health, a developer of virtual nursing simulations, and the 2019 acquisition of 3D4 Medical, the creator of the Complete Anatomy app. In addition, Elsevier launched ClinicalKey Student, an interactive medical education platform equipped with learning tools to support both students and faculty. --- About Complete Anatomy Complete Anatomy from 3D4 Medical by Elsevier is the world's most advanced 3D anatomy platform. The revolutionary cloud-based education platform allows users to investigate the minute detail of the human anatomy in incredible 3D. Complete Anatomy is transforming medical learning and practice across the world, leading the way in the production of groundbreaking 3D medical technology. Featuring over 2.5 million registered customers and over 20 million downloads globally, Complete Anatomy is used daily in over 350 top universities around the world as well as with global clinical organizations. Complete Anatomy’s award-winning software has been featured on stage at Apple and Microsoft events, was honored as the Winner of the Apple Design Awards in 2016, and is the No. 1 top-selling medical category app on iPad in the U.S. 3D4 Medical has been developing medical and anatomical products since 2009 and was acquired by Elsevier in 2019. 3D4 Medical by Elsevier has continued to provide industry-leading innovations that have allowed new ways for students, educators and those in the medical community to learn and understand the human anatomy. To learn more about Complete Anatomy’s female model and the experience it provides users, please visit the 3D4 website. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Media contact Teresa Mueller, Vice President, Global Health Markets Elsevier Communications t.mueller@elsevier.com Contact Details Elsevier Communications Teresa Mueller, Vice President, Global Health Markets +31 6 20987384 t.mueller@elsevier.com Company Website https://www.elsevier.com/

January 10, 2022 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

McDade Products, LLC Joins Forces with G Medical Tests and Services to Provide U.S. Retailers with Millions of COVID-19 at-Home PCR Test Kits

G Medical Innovations Holdings

FDA EUA-approved PCR collection kit tests provide 24-hour certified lab results and retail for $9.99 In response to a national shortage of COVID-19 test options, Pittsburgh-based McDade Products, LLC has partnered with G Medical Tests and Services, a division of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), to manufacture several million U.S. FDA Emergency Use Authorization (EUA) approved COVID-19 PCR collection test kits available for retailers for sale by the end of January, 2022. McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry. McDade Products is now accepting orders for the co-branded LiveNow PCR Collection Kit, which will retail for $9.99. The diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19. Users register with the lab online, collect a nasal swab sample at home, and send the sample to G Medical’s CLIA-certified lab with the pre-paid return pack. On average, tests results are expected to be available online within 24 hours from the time the sample is received. G Medical’s labs are approved by the FDA under the EUA. Currently, G Medical has two CLIA-certified labs; one in Southern California, and the other in North Carolina. In addition, G Medical has launched six testing centers in California, with many more planned. G Medical’s labs are capable of being run 24 hours per day 7 days a week, and can each process up to 24,000 COVID tests per hour to meet the current demand. The first test kit order is for 4 million units. G Medical will be selling these units wholesale for $3.25 each, reflecting gross profit of $7 million. Additionally, G Medical expects to be paid an average of $85.00 per test through each patient’s insurance. According to Grand View Research (grandviewresearch.com) the global PCR and real time PCR molecular diagnostics market was valued at over USD $23.6 Billion in 2020 and expected to expand at a CAGR (compound annual growth rate) of 0.9% between 2021 and 2028. “For decades, we’ve been committed to empowering clinicians and patients to better manage their health outcomes. By partnering with McDade Products, we can make our SARS-CoV2 certified lab testing accessible and convenient for customers and retailers nationwide. With new cases abound, and the world grappling with PCR test shortages there is a tremendous opportunity to provide safety, and relief to the world economy with a significant financial benefit to our shareholders,” said Dr. Yacov Geva, President and CEO of G Medical Innovations. “As a trusted and established next-generation mobile health and e-health company that provides clinical and consumer medical-grade health monitoring solutions, G Medical Innovations enables us to offer our retail customers with an end-to-end solution to address the national shortage of reliable COVID-19 diagnostic tests,” said Michael McDade, CEO of McDade Products, LLC. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders, plans to open Covid-19 testing centers in California, timing of the delivery of tests results, anticipated gross profits, financial benefit to shareholders, and addressing the national shortage of reliable COVID-19 diagnostic tests. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com McDade Products, LLC Jennifer Faines 412-559-2860 Jennifer.faines@gmail.com Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 10, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company

Amorphical

Amorphical’s Novel COVID-19 Oral and Inhaled Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Outstanding preliminary results were revealed in an interim analysis of an on-going Phase II clinical study in Israel for treating patients with moderate-to-severe COVID-19. AMOR-18, a new drug consisting of Amorphical’s unique amorphous calcium carbonate (ACC), was the active pharmaceutical ingredient. The preliminary analysis focused onAMOR-18’s capability of stopping the currently-acute pandemic urgencies from further harming hospitalized patients. Out of a total of 37 patients recruited in one of the study centers, none of the 18 patients taking the drug was transferred to an intensive care unit (ICU) and all were released within a few days from the hospital. In a sharp contrast, 32% of the 19 participants in the placebo group, were transferred to ICU and 10% died. Thus far, sixty-six (66) patients were treated, six (6) in Phase I, fifty-eight (58) in Phase II and two (2) in a compassionate care program. The interim analysis is performed in one of the 4 participating medical centers (Ziv Medical Center) in which 37 moderate-to-severe patients had participated in a randomized, placebo controlled, double-blind study.19 patients were treated with placebo, and 18 patients with AMOR-18. Last week, Amorphical announced that all 18 patients with COVID-19, hospitalized with moderate or severe symptoms, who had received the drug AMOR-18, have recovered and were discharged within a few days. None of the patients treated with the drug were transferred to the intensive care unit or died. By contrast, among the nineteen (19) individuals in the placebo arm, six (6) were transferred to intensive care, and two of them died.As a part of Amorphical’s compassionate care program, two other patients with gravely serious conditions were given the drug outside the study in the same hospital. Both have recovered and were discharged from the hospital. “Since none of the patients receiving the drug (AMOR-18) were transferred to intensive care or died, this interim outcome is a tremendous success for our patients and community”, said Dr. Nashat Abu Saleh, Co-Director of the Coronavirus Department at the Ziv Medical Center in Safed, Israel, where this phase II clinical trial was conducted. Positive Interim Results The ongoing Phase II study (AMCS-COVID-001) is a Prospective, Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, and Efficacy of ACC(named AMOR-18 ), taken daily sublingually and via inhalation administration, concomitantly with Best Available Care (BAT), compared to placebo and BAT. The first efficacy measure assesses the rate of change from baseline to study completion (hospital release or death), as defined by an improvement of 1 or more points on an ordinal 8-point scale. The second measure of efficacy is the ratio of mortality to Intensive Care Unit (ICU) admissions. The preliminary analysis was conducted on a total of 37 patients, equally randomized to treatment with either AMOR-18 (ACC) or a placebo, concomitantly with BAT. Six (6) out of the group of 19 patients (32%) treated with placebo concomitantly with BAT were transferred to the ICU, two of whom died (33%). Conversely, none of the hospitalized patients actively treated with ACC) were transferred to the ICU or died. Dr. Kamal Abu-Jabal, Co-Director of the Outpatient Hospital Unit and ICU COVID-19 Unit at Ziv Medical Center, said: "I believe this treatment has the potential to significantly reduce the mortality rate in patients with moderate-to-severe COVID-19 symptoms and has a broader potential for treating patients who contract similar viral infections. We found safety, effectiveness, and no side effects. Together with the treatment available today for COVID-19, Amor 18 may turn this pandemic to an illness from which one can recover relatively easily, even severely ill hospitalized patients. In our opinion, we are at a turning point of a fundamental change in dealing with COVID-19". Yossi Ben, Founder & CEO of Amorphical, noted: "The interim results bring a great deal of interest among countries and the scientific community. Amorphical is currently conducting several negotiations for such international participation in efforts to combat the pandemic. We intend to provide preferred distribution channels to countries who will support further clinical studies, as well as assist in obtaining regulatory related activities of the drug treatment". The Study at Glance Initially, 6 patients (not included in the reported 37) were recruited for a Training/Safety Study (Phase I) at 3 research hospital sites in Israel. This stage assessed the safety and administration protocol of AMOR- 18 in combined sublingual and inhalable modes. This part of the study concluded that it was safe to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study. The study was originally designed to include 100 patients in total with one-on-one randomization (active + BAT vs. placebo + BAT), and conducting the Phase II study at four medical centers in Israel: Shamir, Ziv, Kaplan, and Mayanei Hayeshua. However, in December 2021, Amorphical conducted an interim analysis of the study on all 37 participating patients in one of the study institutions – Ziv Medical Center. The principal investigators at this Center are Dr. Kamal Abu-Jabal, and Dr. Nashat Abu-Saleh. The interim analysis was conducted due to the vast global spread of COVID-19, a temporary lack of patient candidates in Israel, and anurgent needfor opening study centers outside of Israel. The interim analysis was performed by an independent statistician. The Phase II study in Israel will continue to recruit the intended 100 patients at all the specified hospitals, potentially also including the Wolfson Medical Center-Israel. Preliminary Analysis The study population included 37 patients who tested positive for COVID-19 according to a PCR test and were hospitalized due to the severity of their conditions. After screening, 18 patients were randomly assigned to active treatment group and 19 to a placebo group. The ICU and mortality rate analysis was assessed, along with 95% Wilson Score Confidence Intervals (CI), comparing the study arms with a Cochran-Mantel-Haenszel Test. The Intent to Treat (ITT) analysis set consists of all subjects being randomized. In accordance with the ITT principle, subjects are kept/remain in their originally assigned treatment group. For subjects randomized for treatment by either ACC or placebo, the rate of ICU admittance or death occurred only in the placebo group, and was not observed in the treatment group (p<0.01).All patients in the ACC group tolerated the treatment well, were released from the hospital, and did not report any treatment-related adverse side effects. Further analysis of the interim resultsis on going. According to the preliminary analysis, subjects randomly placed in the active arm (ACC) had a statistically and significantly lower risk of death or ICU admission compared to those randomized into the placebo arm. In the active arm, 0.0% (0/18, 95% CI: [0.00%;17.59%]) of the subjects died or were transferred to the ICU, vs. 31.6% (6/19, 95% CI: 15.36%;53.99%]) in the placebo arm. This difference was highly significant, (p<0.02). The early analysis of the interim results concludes that treating moderate-to-severe COVID-19 hospitalized subjects with ACC AMOR-18is effective in reducing the risk of worsening of the disease. In addition to the goals outlined above, Amorphical has established a compassionate use program, which has treated two additional patients with very severe COVID-19 infection and significant comorbidities. Although these patients did not meet our study inclusion criteria, both responded well to the ACC treatment and were released home. Amorphical plans to complete phase II and immediately proceed to phase III. Phase III will further evaluate the effectiveness of ACC and confirm its safety, tolerability, and efficacy on a global scale. It will then be internationally submitted for prompt regulatory approvals with the intention to support the worldwide efforts against the current and similar future pandemics. Amorphical is currently engaged in approval process with ANVISA (the Brazilian Health Regulatory Agency) to begin recruitment for a similar study with 100 additional patients at 7 hospital sites in Brazil. About the ACC (AMOR-18) Therapeutic Mechanism ACC consists of nanometric and amorphous primary particles, and has much higher solubility & bioavailability than crystalline calcium carbonate (CCC). Amorphical successfully manufactures and markets several dietary supplements based on ACC, which help build, maintain, and restore the body’s health and strength. Preclinical and early clinical studies reveal that ACC provides unique therapeutic and biomedical activities for treating diseases and conditions, associated with acidosis conditionsby directly targeting specific organs or systems. There is a growing body of scientific literature indicating the effects of low pH (metabolic acidosisinside and around organs and cells) on: (a) the progression of SARS-type viruses in general, and COVID-19 in particular; (b) the detrimental impact of excessive acidity on lung inflammation and functions; and (c) the exaggerated immune response (expressed as a cytokine storm), leading to devastating lethal outcomes. In our current study, ACC aims to serve as a pH modulator of the extracellular compartment, inhibiting the virus cell’s penetration, and replication within body cells, and regulating abnormal immune responses. These therapeutic activities are enabled by ACC’s unique amorphous and nanometric state, combined with its carbonate component. These assumed therapeutic activities inspired the current clinical study for treating the entire range of patients suffering from mild-to-severe COVID-19 infection. About Amorphical Amorphical is an Israeli pioneering biotech company, established to develop health and therapeutic products based on amorphous calcium carbonate (ACC). Amorphical has succeeded in synthesizing, stabilizing, and preserving a naturally rare form of calcium carbonate used by nature’s most sophisticated “calcium-producing machine” – the blue crayfish. The synthesis and formulations have been scaled into a manufacturing GMP (Good Manufacturing Practices) operation for supplements in the Arava Desert in Israel. We develop novel solutions for numerous major diseases, based on the uniquely bioactive, nanometric and amorphous ACC. The company has applied for over 130 patent applications in over 40 countries, with over 60 patents already granted worldwide. ( www.amorphical.com )) Contact Details Amorphical Amorphical management info@amorphical.com Company Website https://www.amorphical.com/contact-us/

January 06, 2022 02:00 PM Eastern Standard Time

Image
Article thumbnail News Release

New COVID Testing Centers in Southeastern, North Carolina

COVID Testing Solutions

Today, COVID Testing Solutions™ announced the opening of eight new COVID-19 testing centers in Southeastern North Carolina. The eight new centers are located in Wake County, Asheboro, Southern Pines, Fayetteville, Rockingham, Laurinburg, Wilmington, and Jacksonville. Each center will collect saliva specimens for analysis using the company’s own PCR testing equipment. The goal is to deliver test results within 48-hours in the hope of reducing the spread of the virus. COVID Testing Solutions is prepared operationally to efficiently collect and test specimens from individuals and assist organizations, including churches, schools, and small and large organizations, with their COVID testing needs. The saliva-based (non-nasal probe) PCR test includes indirect indicators of viral load (i.e., level of infection) by measuring Thermal Cycles and can detect COVID-19 infection, regardless of strain, including the delta and omicron variants. The test is available at NO COST with or without insurance. COVID Testing Solutions is affiliated with COVID Treatment Clinics. COVID Treatment Clinics provides personalized, integrated plans that combine conventional and alternative treatment options. The physician-directed plans may include nutritional supplements, pharmaceuticals (monoclonal antibodies), oxygen therapy, and IV therapies. “COVID-19 is far from being contained. Our mission is to provide early testing and treatment that will save lives. Strengthening the immune system through early and individualized intervention is essential to reduce the short- and long-term impact of the disease.” James Taylor, MD COVID Testing Solutions/COVID Treatment Clinics Benefits of COVID Testing Solutions include: 1. No-cost saliva-based testing instead of the nose probe. 2. Quick results. 3. Indirect indicators of viral load which can help direct therapy. 4. Treatment options that go beyond mere bed rest and fluids. Dr. James Taylor created COVID Testing Solutions and COVID Treatment Clinics after his own bout with COVID-19. COVID testing is available today (January 6, 2022) at the Integrated Pain Solutions clinics in Asheboro, Southern Pines, Fayetteville, Rockingham, Laurinburg, Jacksonville, and Wilmington. A dedicated testing center is located in Wake County. COVID-related healthcare services are available for individuals, schools, employers, and organizations. To learn more, go to: COVID19testingsolutions.com or call 910-704-5299. Contact Details Gregory F. Toso +1 610-750-3039 Info@covidtreatmentclinics.com

January 06, 2022 12:00 PM Eastern Standard Time

Image
1 ... 162163164165166 ... 214